Key result
Light transmission aggregometry results in clopidogrel-treated patients depend mainly on the ADP reagent used, with Chrono-Par correctly classifying all CYP2C19*2 carriers as resistant.
Why the study?
Light transmission aggregometry is prone to multiple variables influencing results, yet no attention is currently given to the type of aggregometer or reagent used.
Does the choice of aggregometer and ADP reagent affect the results and interpretation of light transmission aggregometry in patients on clopidogrel?
Cross-Sectional (n=50)
Does the choice of aggregometer and ADP reagent affect the results and interpretation of light transmission aggregometry in patients on clopidogrel?
The choice of ADP reagent significantly impacts the detection of clopidogrel resistance by light transmission aggregometry, highlighting the need for standardized laboratory methodologies.
ADP reagent choice may alter LTA-based clopidogrel resistance classification; leaves open standardization needs for reliable clinical and research use.
Introduction Light transmission aggregometry (LTA), used to detect clopidogrel resistance in patients under antiplatelet therapy, is prone to multiple variables potentially influencing results and interpretation. Currently, no attention is given to type of aggregometer or reagent used. The aim of this study was to evaluate the interassay variability between two aggregometers (Chronolog700 and TA‐8V), using two different ADP reagents (Chrono‐Par ® and Agro‐Bio ADP) in patients under clopidogrel therapy. Additionally, LTA results were correlated to CYP2C19 ‐polymorphism. Methods Light transmission aggregometry was performed in 20 healthy individuals and 30 patients using both aggregometers, and applying two different reagents (2.5 and 5 µmol/L). The maximum platelet aggregation (ADP max ), the platelet aggregation at 6 minutes (ADP 6min ), and the percentage of disaggregation at 6 min (ADP %disaggr ) were compared between four applied combinations. Additionally, 23 clopidogrel‐resistant patients according to Chronolog700‐Chrono‐par ® ADP reagent analysis were tested for CYP2C19*2 polymorphism. Results Comparison of the LTA of healthy individuals revealed a significant lower ADP max , lower ADP 6min , and higher ADP %disaggr with the TA‐8V aggregometer compared to Chronolog700, regardless of the reagent. In contrast, LTA results in patients are depending on the reagent, with significant higher ADP max and ADP 6min and lower ADP %disaggr using Chrono‐Par ® compared to Agro‐Bio ADP reagent. All intermediate clopidogrel metabolizers ( CYP2C19*2 carriers) were correctly classified as clopidogrel resistant using Chrono‐Par ® , in contrast to the Agro‐Bio ADP reagent. Conclusion Light transmission aggregometry in clopidogrel‐treated patients is mainly depending on the type of ADP reagent. Comparison of LTA with genotype reveals that the choice of instrument seems less influencing. In contrast, in the healthy individuals, differences could be attributed to the instrument.
No takes yet. Share an insight, caveat, or question.
Monteyne et al. (2021) conducted a cross-sectional in Patients under clopidogrel therapy and healthy individuals (n=50). Light transmission aggregometry (LTA) with different aggregometers and ADP reagents vs. Comparison between Chronolog700 and TA-8V aggregometers, and Chrono-Par and Agro-Bio ADP reagents was evaluated on Maximum platelet aggregation (ADP max), platelet aggregation at 6 minutes (ADP 6min), and percentage of disaggregation at 6 min (ADP %disaggr). Light transmission aggregometry results in clopidogrel-treated patients depend mainly on the ADP reagent used, with Chrono-Par correctly classifying all CYP2C19*2 carriers as resistant.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: